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Background: The Head and Neck Cancer Working Group of Swiss Group for Clinical
Cancer Research (SAKK) has investigated the level of consensus (LOC) and discrepancy
in everyday practice of diagnosis and treatment in head and neck cancer.
Materials and Methods: An online survey was iteratively generated with 10 Swiss
university and teaching hospitals. LOC below 50% was defined as no agreement, while
higher LOC were arbitrarily categorized as low (51–74%), moderate (75–84%), and
high (≥85%).
Results: Any LOC was achieved in 62% of topics (n = 60). High, moderate, and low
LOC were found in 18, 20, and 23%, respectively. Regarding Head and Neck Surgery,
Radiation Oncology, Medical Oncology, and biomarkers, LOC was achieved in 50, 57,
83, and 43%, respectively.
Conclusions: Consensus on clinical topics is rather low for surgeons and
radiation oncologists. The questions discussed might highlight discrepancies, stimulate
standardization of practice, and prioritize topics for future clinical research.
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INTRODUCTION
This is the second part of the article “A Review of Controversial
Issues in the Management of Head and Neck Cancer: A Swiss
Multidisciplinary andMulti-Institutional Patterns of Care Study,”
providing the results for the items concerning radiation oncology
discipline, each followed by a short discussion if deemed relevant.
The details of the methodology is presented in the first part of
this series.
RESULTS AND DISCUSSION
Radiation Oncology
Definition and Compartmentalization of Target
Volumes
â Omitting the elective treatment of the contralateral neck
is safe in well-lateralized primaries of the tonsil: moderate
LOC (80%).
For a cT2 carcinoma of the tonsil, the uninvolved contralateral
neck is omitted if the tumor is well lateralized and with <10mm
of the superficial mucosa of soft palate and/or base of tongue
in 8/10 centers. The remaining two centers always perform
bilateral treatment.
Although no prospective randomized trial was performed to
exclusively answer this question, there is mounting evidence
to support the safety of ipsilateral treatment of well-lateralized
OPSCC. As endorsed by the American College of Radiologists,
treatment can be limited to the ipsilateral side in tonsil primaries
with a N0-1 nodal stage when the primary exhibits <1 cm
invasion into the soft palate or base of tongue (1). Other
retrospective series also showed excellent results with N2b or
unilateral N3 cases (2–4) and in other oropharyngeal (2, 5) as well
as oral cavity subsites (6). However, no prospective randomized
trial results for this question are available. In the recently updated
international consensus guidelines, this issue is still regarded as
controversial, and caution is advised especially for nodal stages
above N2a (7).
â Compartmentalization of the tumor bed and the levels of the
nodal basin for post-operative radiotherapy in terms of dose
and volume: no consensus.
In 3/10 centers, the post-operative primary tumor bed is
not included in the target volumes, if the indication for
adjuvant radiotherapy arises only due to nodal factors after neck
dissection. The remaining 7 centers do not separate the tumor
bed and the dissected nodal levels.
Similarly, regarding the elective/low risk volumes in the post-
operative setting, in 5/10 centers the whole post-operative neck is
considered as an inseparable target compartment. In the other half
of the centers, the levels are thought of separable compartments,
and, in eligible cases based on the nodal distribution pattern
reported by the pathology, radiotherapy to a portion/level of the
post-operative neck is omitted.
The selection of radiotherapy target volumes is strongly
influenced by tradition. More than a decade ago, the landmark
EORTC 22931 and RTOG 9501 trials defined the major and
minor risk factors for the indications of post-operative CRT and
radiotherapy, respectively. However, the question of the necessity
of such an “all or nothing” approach concerning different parts
of the target volume(s) remains unanswered. Surely, one of the
arguments for irradiating the primary tumor bed in case of
multiple nodes with or without ECE has been the general loco-
regional recurrence risk and difficulties to irradiate the primary
tumor recurrences after previous nodal irradiation, especially in
the past due to technical limitations. Nevertheless, from a purely
medical and not a technical perspective, it is not clear, why the
post-operative primary tumor bed should be irradiated due to
multiple nodal positivity and/or ECE, whereas the same patient
and tumor bed would not receive any radiation if the neck would
have been pN0-1. Similarly, there is no data indicating perineural
extension as a risk factor for nodal recurrence.
Concerning the post-operative nodal target volume, half of the
radiation oncologists still treat the entire surgical bed covering
both the primary tumor bed and the operated neck (at least the
involved side). On the other hand concerning the post-operative
primary tumor target volume, most oncologists still treat the
entire surgical bed at least within a low risk volume irrespective
of risk factors specifically related to the primary tumor or the
neck (8). Nevertheless, the recently demonstrated long-term
results of a prospective phase II study supports the safety of
this compartmentalization approach (9). On the contrary, data
indicating the risk of compartmentalization approaches also exist
(10). However, such retrospective studies reporting unusually
high recurrence rates should be critically interpreted in the lack
of description of surgical techniques and radiotherapy approach
especially in terms of online and oﬄine image guidance protocols
within the frame of the limited volume approach.
â Adaptation of the dose or target volumes (except for
the replacement of anatomical barriers) after induction
chemotherapy is not preferred: moderate LOC (80%).
After an induction chemotherapy, 8/10 centers would not adapt
the dose or target volume (except for anatomical changes)
regardless of a partial or complete response. In one center
clinical target volume (CTV) would be adapted based on tumor
shrinkage. In another center, both dose and volume would be
de-escalated based on response.
For radiotherapy planning after induction chemotherapy
radiotherapy, Salama et al. (11) recommended the irradiation of
pre-induction volumes with full dose even in case of a clinical
complete response while taking the volumetric changes in
anatomical structures and barriers into consideration. Despite
of that, there is a substantial heterogeneity in target volume
definition concepts among different institutions (12, 13).
Although not part of the main scientific question and primary
endpoint, the target volumes and prescribed doses after a clinical
response to induction chemotherapy were adapted in some
contemporary prospective clinical trials (13, 14). In a recently
published phase III randomized trial the non-adapted and
adapted volume approaches after induction chemotherapy for
nasopharyngeal cancer were compared (15). The investigators
did not report any inferior oncologic outcome with the adapted
strategy. However, volume reduction did not result in a
substantial reduction of toxicity or improvement in quality of
life except for a few among the many investigated domains.
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It is also worth to note, that this study was underpowered to
detect a non-inferiority in oncologic outcome in this regard.
Moreover, there are quantitative analyses indicating that it is
unsafe to adapt the high-risk volume based on the shrinkage of
the macroscopically visible tumor in radiological imaging after a
non-definitive treatment (16).
â Definition of treatment volumes for the treatment of CUP:
no consensus.
No consensus was reached concerning the treatment volumes
in CUP situation. Treatment volumes of a CUP always contain
bilateral neck and potential mucosal sites (4/10); only the
involved side(s) of the neck (3/10); and involved side(s)
plus corresponding mucosal sites only in case of human
papillomavirus (HPV) or Epstein-Barr Virus (EBV) positivity
(2/10). One center always treats the mucosal sites but only with
the involved side(s) of the neck.
The literature about the optimal management of CUP is
conflicting. There is no convincing data supporting the elective
irradiation of the contralateral uninvolved neck in the modern
series (17–19), whereas the reports indicating the superiority of
bilateral irradiation are outdated in terms of radiotherapy and
imaging modalities (20). Some facts are worth considering for
the selection of the optimal strategy (21–25): (1) The risk of
nodal recurrence and distant metastases is at least twice higher
than the subsequent appearance of a mucosal primary tumor
(≤10%). (2) The emergence rates of mucosal primary tumors after
unilateral neck irradiation are similar to the risk of occurrence
of metachronous second primary tumors in patients cured of a
known head and neck SCC primary. (3) Survival rates are not
related to the appearance of the primary tumor (21, 22, 26). Last
but not least, doubling the target volume by means of bilateral
irradiation substantially contributes to the toxicity burden, which
would outweigh any marginal oncological benefit, which rather
seems non-existent (18, 19).
â Use of an isotropic margin and respecting the anatomical
barriers is the preferred method to generate high-risk CTVs
around the gross tumor volume (GTV): low LOC (60%).
When contouring the high risk CTV around the primary tumor,
3/10 centers use the predefined anatomical subsites defined by
Eisbruch et al. (27). One center treats these sites with 60Gy
by using an intermediate risk volume. The rest of the centers
only use an anatomical isotropic margin and crop this volume
from the anatomical barriers as suggested by Caudell et al. (28),
who also reported a non-inferior outcome with the geometric
extension approach compared to treatments with predefined
anatomical subsites.
The survey was completed before the recent publication of the
international consensus guidelines for the delineation of the
primary tumor CTV by Grégoire et al. (29), in which the isotropic
geometric expansion concept was also endorsed. These guidelines
recommend the use of 5 and 10mm around the GTV for high-
risk and prophylactic CTVs, respectively. Nevertheless, these
volumes shall be manually cropped by taking the anatomical
barriers into account. The exceptions to this rule were defined
for early stage glottic and locally-advanced stage hypopharyngeal
primaries. For the former, prophylactic volumes were deemed
unnecessary, whereas for the latter, a 15mmmargin in the cranio-
caudal direction was suggested.
â A restricted use of intermediate-risk dose only in the levels with
ECE is preferred: high LOC (90%).
In case of pathologically-confirmed ECE, only the involved levels
are treated with an intermediate dose of 60–66Gy in 9/10 centers.
The rest of the neck is treated with an elective/low-risk dose. In
one center, all involved levels are treated with 64Gy irrespective
of ECE, and the uninvolved levels are treated with a lower dose,
since systematical anatomical marking of the lymph node levels
on the surgical specimen is not performed sufficiently.
Traditionally, some head and neck cancer oncologists were
concerned about the intraoperative spillage of the tumor cells,
in case of ECE and/or positive resection margins. However,
even in the twin landmark RTOG (9501) (30) and EORTC
(22931) (31) trials, only the high risk areas were boosted up to
60–66Gy. In the current international consensus guidelines for
the delineation of nodal target volumes, a compartmentalized
approach is recommended. It is worth to note, that the evidence
level supporting the inclusion of non-involved postoperative
levels into the prophylactic volumes even in the N+ neck is
low, and this approach is rather based on tradition (8, 27).
Nevertheless, it seems, that it is not always possible for the
radiation oncologists of these 9 centers to compartmentalize
the intermediate-risk volume, since only 4 centers systematically
mark the lymph node levels on the surgical specimen before
sending them to the pathology.
â Use of tailored planning target volumes (PTV) for different
anatomical subsites: no consensus.
In some anatomical subsites (e.g., larynx, tongue, soft palate),
4/10 centers use additional geometric margins concept to
compensate for possible organ movement. In one of these
centers, an anisotropic margin for larynx and soft palate
primaries are used. For the remaining 6 centers, such an internal
target volume concept is not used based on subsite. On the
other hand, the policy of these centers is to re-plan and adapt
the margins according to movement based on daily imaging, if
considered necessary.
The conventional fields in the 2D radiotherapy era encompassed
the target volumes with enough margins to compensate for
movement. As an example, the larynx is known to move
up to 20–25mm craniocaudally (32, 33). Despite of that,
the traditional 2D fields did not require further enlargement
due to the technical features of 2D-conventional radiotherapy
(32). However, the sharp dose fall-off profile of intensity-
modulated radiotherapy (IMRT) to spare sensitive tissues
allows less tolerance for target volume delineation errors
and marginal misses. Studies performed with volumetric
imaging and dynamic MRI demonstrated the necessity of extra
margins of 5mm to every, and 6–7mm to cranial direction
for the primaries of soft palate, larynx, and hypopharynx
(34, 35). Recently published data by Bruijnen et al. (36)
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demonstrate considerably shorter ranges of intrafractional tumor
motion <3mm (95th percentile—excluding swallowing) with
a decreasing order from laryngeal to oropharyngeal and
nasopharyngeal primaries, respectively. However, in addition to
intrafractional, the interfractional positional differences of soft
palate, uvula, larynx, and tongue; moreover, the elastic changes
in the relationship of different subvolumes of PTV [e.g., primary
tumor and involved lymph node(s)] are more difficult to quantify
and to tackle with. Unacceptable variations seen with daily
imaging should lead to adaptive re-planning as quickly as possible.
As a less systematically reported issue, swallowing frequency, and
positional changes in the pharyngo-laryngeal anatomy during the
treatment may be associated with changing treatment anxiety,
consistency of saliva, and increasing mucositis throughout the
course of treatment.
â Definition of high- and low-risk volumes for laryngeal
primaries: no consensus.
Laryngeal primaries are treated by including the whole larynx
in the high-risk volume in 2/10 centers. Five centers prefer to
treat the primary tumor with a predefined margin. In the rest of
the centers, the larynx (in one center the involved hemilarynx)
is considered as a compartment which shall be treated with an
elective dose. The primary tumor is treated to a high dose with a
predefined margin.
The 3D volume definition for laryngeal primaries was just a
translation of traditional 2D fields to the 3D era. This resulted
in the continuation of treating the whole larynx within the
high-risk volume receiving the highest dose, even for early
stage tumors without infiltration to cartilaginous structures,
contralateral extension, etc. This concept is still being used in
some centers. At the other end of the spectrum, hemilarynx
(37, 38), even single vocal cord irradiation (39) techniques were
developed for early stage laryngeal primaries, yielding excellent
results. For locally advanced laryngeal primaries, the inclusion
of the whole larynx into the prophylactic target volumes is not
recommended anymore by current consensus guidelines (29).
Dose and Fractionation Concepts
â The use of simultaneous integrated boost (SIB) is the preferred
boost technique: moderate LOC (80%).
Centers were asked to provide information about the boost
techniques and dose/fractionation regimens for target volumes
(Table 1). Simultaneous integrated boost (SIB) and sequential
boost (SEQ) techniques are used in 8 and 2 centers, respectively.
IMRTwith inverse planning allows SIB tomultiple target volumes
during the course of radiotherapy by means of a dose painting
approach. The beams used to deliver the planned dose to the high-
risk volume are exploited for the dose application to the encircling
low-risk volume(s). In contrast to the traditional sequential
shrinking field/volume approach, SIB enables the generation of
single-phase plans with the possibility of a more flexible plan
optimization process. This allows an advantage over SEQ in
terms of better control of dose around the high risk PTV and
reducing the unwanted high dose areas within. Although there are
countless retrospective and prospective studies, in which patients
were treated with SIB, no prospective randomized trial compared
both technical modalities until recently. Lertbutsayanukul et al.
(40) conducted a phase III randomized trial with the primary
endpoint of acute and late toxicities during and after SIB vs.
SEQ for the treatment of nasopharyngeal cancer. This study with
a superiority design did not show any statistically or clinically
significant difference in toxicity or oncologic endpoints. In theory,
similar studies including other four major HNSCC subsites are
needed. However, the toxicity results reported by Lertbutsaanukul
et al. can be extrapolated to other subsites, considering the fact,
that the treatment of nasopharyngeal cancer involves the largest
and most complex target volume and organs at risk in the head
and neck area.
â Hypofractionation for the treatment of early stage glottic larynx
cancer: no consensus.
For early stage glottic larynx cancer, 4/10 centers perform
hypofractionated radiotherapy (≥2.25Gy per fraction).
There is mounting evidence supporting the shortened treatment
time in the treatment of stage I-II glottic larynx cancer for
increased tumor control (41). Reports on large series from
cancer registries (42, 43), prospective clinical databases (44),
meta-analyses (41), and prospective randomized trials (45–47)
demonstrated favorable results with altered fractionation either
by means of hypofractionation and/or acceleration. The possible
effect of hypofractionation is probably based on its treatment-
accelerating effect, rather than the exploitation of the β value (44,
45, 48, 49). As reported so far, long-term toxicity is not a major
point of concernwith accelerated ormoderately-hypofractionated
irradiation (46, 47, 50), which is in line with the biological
rationale regarding the time factor (49). It can be safely applied
andmay be preferred due to its benefits in terms of costs, logistics,
and patient comfort. Hypothetically, the therapeutic window
may also be widened with the use of contemporary treatment
techniques (39). In this regard, impressive clinical results of a
prospective study using SBRT (58.08Gy in 16 fractions) with the
primary endpoint of voice quality deserves attention (39): 2 years
local control and overall survival of 100 and 90%, respectively,
without any grade 3 or above toxicity. When compared with a
historical control group, which was treated to the whole larynx
(66Gy in 33 fractions), single vocal cord irradiation yielded less
grade ≥2 acute toxicity (17 vs. 66%, p < 0.01) and lower voice
handicap index scores in almost all follow-up visits performed in
regular short intervals until 18th month (p < 0.01). In contrast, a
recently published phase I trial with extremely hypofractionated
radiotherapy using robotic SBRT yielded inferior local control
and not necessarily less toxicity compared to the literature (51).
This was possibly because of the irregular laryngeal motions
occurring during a protracted dose delivery and the lack of the
current robotic SBRT unit’s capability to handle them.
â Altered fractionation is preferred in case of radiotherapy
without concomitant systemic agents: moderate LOC (70%).
Altered fractionation is used in 7/10 centers. In the
corresponding question, altered fractionation was defined
as any treatment not fitting to the following arbitrary description
in the questionnaire: single fraction/day throughout the
whole treatment course with a fraction size between 1.8 and
2.2Gy for the high-risk volume. The distribution among the
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TABLE 1 | Dose-fractionation schedules for definitive (chemo)radiotherapy.
Center 1 2 3 4 5 6 7 8 9 10
High risk dose (Gy)/fractions 69.96/33 72/36 70/35 66/30 69.63/33 70/35 69.3/33 70–76/35-38* 69.63/33# 70/33
Intermediate risk dose (Gy)/fractions 59.4/33 66/33 66/33 60/30 66/33 60/35 56.1/33 64/32 60/33 59.4/33
Low risk dose (Gy)/fractions 52.8/33 54/30 50/25 54/30 56/33 54/35 52.8/33 50–54/25-27* 54/33 52.8/33
Boost technique SIB SIB SEQ SIB SIB SIB SIB SEQ SIB SIB
SEQ, sequential boost; SIB, simultaneous integrated boost.
*Higher dose in case of no concomitant systemic therapy.
#70Gy in 35 fractions for “large” tumors.
altered fractionation regimens were as following: acceleration
(six fractions per week or concomitant boost) in 6 centers,
hyperfractionation in 3 centers (two centers use both strategies).
Three centers combine systemic agents with hyperfractionation
and/or acceleration.
Compared to normofractionated radiotherapy, the survival and
loco-regional control benefit of altered fractionation is proven,
particularly in the form of hyperfractionation in the definitive
radiotherapy setting without concomitant systemic treatment
(52). However, this added benefit of altered fractionation wanes
out with increasing age (53), most probably due to competing
risks for death, such as comorbidities. Therefore, the role
of altered fractionation may be questioned in the selected
elderly and/or fragile patients who are deemed not to tolerate
systemic treatment.
There are numerous combinations of systemic agents and altered
fractionation schedules for the treatment of HNSCC (54). In
summary, there seems to be no benefit of combining accelerated
fractionation and concomitant chemotherapy. For example, the
GORTEC 99-02 trial randomized 840 patients into three arms
with the primary endpoint as loco-regional control. In one of the
two arms with chemotherapy (carboplatin and 5-fluorouracil),
patients received 70Gy in 35 fractions over 7 weeks, and in
the other arm 70Gy in 40 fractions over 6 weeks (40Gy in 20
fractions over 4 weeks followed by 30Gy in 20 fractions over 2
weeks). At 7 years, the difference in outcome was statistically not
significant among the arms. Acute mucositis and feeding tube
requirement were higher with accelerated radiotherapy by means
of concomitant boost and chemotherapy than normofractionated
radiotherapy and chemotherapy. Late toxicities were comparable
(55, 56). The RTOG 0129 randomized 743 patients into two arms,
both with concomitant cisplatin: normofractionated radiotherapy
(70Gy in 35 fractions over 7 weeks with three cycles of cisplatin)
versus accelerated radiotherapy by means of concomitant boost
(36Gy in 18 fractions over 3.5 weeks followed by 36Gy in
24 fractions over 1.5 weeks with two cycles of cisplatin). At
8 years, no significant difference in overall survival (primary
endpoint), any oncological endpoints, or acute and late toxicities
was observed (57). The question left unanswered is whether
there would be an added benefit of combining hyperfractionated
radiotherapy and concomitant chemotherapy compared to
conventionally fractionated radiotherapy and chemotherapy. The
statistical models indicate a potential advantage in this regard
(58), which needs to be confirmed by prospective randomized
trials. Unfortunately, it is quite unlikely to witness any large-
scale trials conducted to answer this question due to the lack
of financial attractiveness for the industry. The EORTC 22962
trial would have been the ideal phase III study with four
arms, comparing normofractionated radiotherapy (70Gy in 35
fractions) with hyperfractionated radiotherapy (80.5Gy in 70
fractions) in 7 weeks with or without cisplatin. Unfortunately, the
trial terminated prematurely due to slow accrual after recruiting
only 57 patients. The above-mentioned RTOG 0129 was designed
with the MD Anderson combined boost schedule. It is unknown
what would have happened if the hyperfractionated arm of the
RTOG 9003 (59) was chosen instead of the accelerated regimen.
â There is no standard in terms of dose prescription and plan
normalization: no consensus.
During the radiotherapy planning process, 5/9 centers use the
median dose to PTV for dose prescription. Of those, only
2 centers normalize the plan according to a minimum dose
coverage criterion (e.g., D95% = 95% of the prescribed dose).
The authors of the ICRU 83 report (60) only suggested to
prescribe on the median absorbed dose to the target volume
(D50%), but without a strict restriction of the use other dose-
volume prescription values. In practice, there is a large variety
in internal clinic protocols and clinical trial protocols. As
an example, in the modern EORTC trials for HNSCC (e.g.,
NCT02984410, NCT01880359), it is requested to prescribe the
dose on D50%, and obtain a dose coverage of at least 95% of the
prescribed dose to the 95% of the PTV, whereas normalization
to D95% instead of D50% is demanded in the RTOG protocols
(e.g., NCT01302834, NCT01953952, NCT00265941). It is likely,
that no consensus will exist in the near future. Nevertheless, it is
important to be aware of these differences to correctly implement
the dose, fractionation, and incorporate new techniques used in
clinical trials into routine practice.
Evaluation of the Treatment Response
â Refer to Table 2 for LOC for each post-treatment response
evaluation modality for the neck.
The participating centers were asked to provide their post-
(chemo)radiotherapy response evaluation schedules, which are
summarized in Table 2. Morphologic and metabolic imaging
modalities are the most frequently (8/10 for each) used tools
for the assessment of treatment response, whereas there is a
prominent heterogeneity regarding the regular use of physical
examination, ultrasound (± fine-needle aspiration) and the time
interval to perform these imaging examinations. There is no
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TABLE 2 | Post-(chemo)radiotherapy response evaluation schemes for stage III-IV/B disease.
Center (LOC) 1 2 3 4 5 6 7 8 9 10
Physical examination
(no)
X X X X
Morphologic imaging
(moderate)
X X X X X X X X
Metabolic imaging
(moderate)
X X X X X X X X
Regular ultrasound ± FNA
(moderate)
X X X X X X X
Time interval for the
post-treatment imaging in
weeks
(high LOC around 12, but no
LOC for a strict time frame)
8–12 6–8 12–16 10–12 4–12 8–12 12 12 6–12 10–12
FNA, fine-needle aspiration; LOC, level of consensus.
TABLE 3 | Dose-fractionation schedules for palliative radiotherapy.
Center 1 2 3 4 5 6 7 8 9 10
Preferred regimen (dose in Gy/fraction) None 50/20 QS None QS QS* or 37.5/15# 40/16 or 45/18 42/13* or 12/2# QS* or 25/5# None
Number of fractions/week NA 5 4 NA 4 4* or 5# 5 5* or 2# 4* or 5# NA
NA, not available; QS, Quad-Shot, i.e., 3 cycles of (4 × 3.5–3.75Gy BID in 2 days) each 4 weeks apart.
*,#The values with these signs under each column correspond to the preferred regimen and the number of fractions under the same column.
center, in which no regular post-treatment response evaluation
imaging is performed.
Although there is no international consensus about the post-
(chemo)radiotherapy response evaluation tools and the optimal
time interval, the highest level of evidence was generated by the
PET/NECK Trial (61), which demonstrated the futility of the
planned neck dissection approach after CRT. Despite of being a
relatively expensive imagingmodality on its own, 18FDG-PET/CT
is indeed cost-effective (62) compared to planned neck dissection
and yields similar outcome in terms of survival and quality of
life (61).
For response evaluation, 18FDG-PET/CT is reported to have
a higher accuracy in the detection of recurrent lesions when
compared to CT and MRI (63). Its negative predictive value is
very high, but the positive predictive value is suboptimal. In other
words, 18FDG-PET/CT is an ideal modality to rule out residual
disease after (chemo)radiotherapy. Recent studies demonstrated
further increased accuracy with delayed image acquisition around
16 weeks after treatment with NPVs reaching 100% (64–66).
On the other hand, the access to 18FDG-PET/CT in low-cost
setting is not always warranted, and morphologic imaging alone
with MRI or CT should be relied on. Another well-known issue
is the delayed response in involved lymph nodes of HPV+
oropharyngeal tumors (67), which sometimes exceeds 24 weeks
after the end of treatment. Such patients are under increased risk
of undergoing unnecessary biopsies and salvage neck dissections.
Nevertheless, that does not mean, that the suspicious findings
which indicate an incomplete remission (regardless of HPV
status) can be left to routine clinical observation without
performing a timely pathology examination.
The rationale of a regular ultrasound ± fine-needle
aspiration policy (regardless of clinical response) is not
clear, especially if the above-mentioned imaging modalities are
already planned.
Palliative Radiotherapy and Salvage Re-Irradiation
â No particular preference exists for palliative radiotherapy
regimens: no consensus.
Among centers, there was a heterogeneity in palliative
radiotherapy regimens. Three centers did not provide any
preferred regimen. The most frequently mentioned regimen
was the Australian Quad-Shot (4/10). Details are provided in
Table 3.
There are various radiotherapy regimens for the palliative
treatment of head and neck cancer (68). In the lack of evidence
to back a particular dose-fractionation regimen, the following
aspects of palliative radiotherapy concept should be considered.
Shorter treatment time and hospital visits play an important
role for patient comfort. Hypofractionation and split-course
regimens are safe in palliative setting (69). However, previously
applied doses and normal tissue reserves should be always
taken into consideration when choosing the optimal dose and
fractionation. The use of IMRT is recommended to further
minimize treatment toxicity.
â Hypofractionated stereotactic body radiotherapy (SBRT) is
considered in re-irradiation setting with curative intent: low
LOC (60%).
â SBRT is considered for palliative irradiation: low LOC (60%).
SBRT is performed in (or via referral to another center)
6/10 centers with an indication for re-irradiation with a
curative intent. In 6/10 centers (partially overlapping with
the former) it is used for palliative treatments. In one
center, it is also used to apply the boost dose following
the elective course of radiotherapy. In 2/10 centers it is
never used.
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Various applications of SBRT in head and neck
cancer are reported (its use in glottic larynx cancer is
mentioned previously):
1) Prospective clinical trials investigated the role of SBRT
in re-irradiation of unresectable recurrences. The dose
fractionation schedules were extremely hypofractionated
(70–72). Although no head-to-head comparisons exist, the
survival rates seem to be not inferior to normofractionated
(73, 74) or hyperfractionted (75, 76) schedules, and the
toxicity profiles look comparable with slightly being superior
(77). The last phase II trial (n = 50) demonstrated 6% acute
and 6% late grade 3 toxicity rates with 40–44Gy in five
fractions over 2 weeks (72). The same group also published the
largest retrospective series so far (n = 291) (78). The results
of this study indicate, that the SBRT is safe and effective.
Nevertheless, due to higher risk for late toxicity, the laryngeal
and hypopharyngeal primaries should be carefully selected
(72, 78).
IMRT appears to be a feasible alternative as well
(77). Recently, the Multi-Institution ReIrradiation (MIRI)
Collaborative defined three classes of re-irradiated patients
treated with IMRT by means of recursive partitioning analysis
(RPA). RPA class I (>2 years after initial radiotherapy with
resected tumors; 2 years overall survival: 62%) outperformed
the class II (>2 years with unresected tumors or <2 years and
without tracheostomy or feeding tube dependence; 2 years
overall survival: 40%) and class III (remaining patients; 2
years overall survival: 17%) (79). Despite a potential selection
bias due to the retrospective nature of the data, MIRI also
demonstrated the redundancy of elective nodal irradiation
and hyperfractionation regarding loco-regional control and
overall survival. The same work indicated the need to
administer ≥66Gy equal dose in 2Gy fractions to unresected
tumors (80). This dose-tumor control relationship with
conventional fractionation is also supported by the findings
of a recent systematic review by the AAPM Working Group
about hypofractionated SBRT, which shows superior tumor
control with similar biologically 2 Gy/fraction equivalent
doses of >35Gy in 5 fractions, and suggests to administer
40–50Gy in 5 fractions if possible (81).
In another multi-institutional study, re-irradiation cohorts
of IMRT and SBRT were compared using the same MIRI RPA
classes II and III (no class I due to lack of operated patients).
SBRT was associated with slightly less toxicity than IMRT
(Grade ≥4 5.1% vs. 0.5%, p < 0.01). Both techniques showed
similar overall survival in RPA class III, but significantly
better survival with IMRT in class II. Comparable overall
survival and loco-regional control were reported on RPA
class II small tumors (≤25 cm3) with SBRT (>35Gy in ≤5
fractions) and IMRT (77). After adjustment for potential
confounders, SBRT and IMRT yielded similar overall survival
and loco-regional control in the whole cohort. Either way, the
patients seem to benefit from advanced technology by means
of SBRT or IMRT compared to conventional techniques.
Therefore, conservative reluctance to re-irradiation should
be re-questioned. Validated tools for better patient selection
criteria and prospective randomized studies to define the
optimal strategies in re-irradiation setting are needed.
2) The Erasmus MC group published their results of T1–2
OPSCC cases treated with either pulsed-dose brachytherapy
(n = 148; 22Gy in 8 fractions over 24 h) or SBRT (n = 102;
16.5Gy in 3 fractions over 1 week) boost following 46Gy
in 23 fractions with concomitant cisplatin (82). Toxicity and
quality-of-life scores were comparable with both modalities.
The authors favored the use of the non-invasive SBRT
strategy, mainly based on the fact that it is less labor intensive,
while brachytherapy is associated with perioperative and
anesthesia-associated complications and requires specially
trained personnel with hand dexterity.
CONCLUSION
The findings of our survey indicate a low LOC among head
and neck oncologists working in academic and multidisciplinary
setting in 10 Swiss institutions. Regarding the results and
the discussion concerning the specialties other than radiation
oncology, the reader is advised to read the corresponding parts
of this article. The highest LOC was achieved among medical
oncologists, whereas the lowest was observed among head and
neck surgeons. On the other hand, this level of disagreement
may also depend on the topics chosen for the survey, and not
necessarily the heterogeneity within the disciplines. It is also
interesting to witness a low LOC regarding topics, where a
high level of evidence actually does exist, and vice versa, such
as definition of post-induction chemotherapy or post-operative
treatment volumes, diagnostic modalities and time interval used
to evaluate treatment response, use of boost techniques and
dose/fractionation in early stage glottic laryngeal cancer. This
article is expected to serve the head and neck oncologists to be
aware of their discrepancies even among academic institutions
and to stimulate discussion toward standardization of practice
and prioritize topics of future clinical research. We support
the concept of and the adherence to standardized guidelines,
which should address controversial but relevant topics as well.
Importantly, the level of evidence or the lack of thereof should
always accompany the guideline recommendations. Last but not
least, we would like to emphasize that this article series is not a
literature review in the classical sense.
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